Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly

Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.

Investors Business Daily

Novo Nordisk Stock Flashing Renewed Technical Strength

Novo Nordisk ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Patients complain some obesity care startups offer pills, and not much else

Many Americans turn to the latest big idea to lose weight — fad diets, fitness crazes, dodgy herbs and pills, bariatric surgery, just to name a few. They’re rarely the magic solution people dream of.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Concerns rise over obesity care startups

Concerns emerge over a wave of new startups offering access to drugs called GLP-1 agonists

Salon

Weight loss drug causing chaos on TikTok

A diabetes drug is all the rage among Hollywood’s elite, but folks who need the drug are struggling to get it

Salon

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Independent UK

Eli Lilly Dives After Fake Twitter Account Promises Free Insulin; Takes Novo Nordisk, Sanofi With It

Twitter's new verification system shook Eli Lilly — leading LLY stock to skid Friday — after a fake account claimed "insulin is free now."

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

‘I miss eating’: the truth behind the weight loss drug that makes food repulsive

In Beverly Hills’ doctors offices, celebrities are clamoring for Ozempic prescriptions – but what are the costs of the supposed wonder drug?

The Guardian - US

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Investors Business Daily

How Novo Nordisk Is Trying To Lengthen Its Lead In Weight Loss Over Eli Lilly

Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.

Investors Business Daily

Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments

Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.

Investors Business Daily

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying.

Investors Business Daily

Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock

Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Stocks No One Is Talking About but Should Be

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan Machinery (TITN) are currently not on investors’ radar, but it could be worth adding these stocks to one’s portfolio given…

Investors Business Daily

Coal Stocks Today: Why Alliance Resource Partners Remains A Stock Market Leader

Fund ownership has been increasing at Alliance Resource in at least the past three quarters.

Financial Times

A new ‘miracle’ weight-loss drug really works — raising huge questions

Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

Investors Business Daily

IBD Screen Of The Day: Mutual Funds Are Buying These Energy Stocks

Why solar, oil, and drug stocks may be ones to add to your watchlist.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Upgrades

Investors Business Daily

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

The Dow Jones rose despite a recession warning from Fed Chair Jerome Powell. Bitcoin tumbled again. Apple stock rose after a bullish call.

Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Tribune News Service

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

1 … 19 20 21 22

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.